CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
abiraterone acetate +1 moredrug
Likely dose
abiraterone acetate 1,000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01309672
NCT01309672Phase 2Completed
CompareCT.gov

Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II

SWOG Cancer Research Network·interventional·Posted Mar 7, 2011·Updated Feb 26, 2025

In Brief

A Phase 2 clinical trial evaluating abiraterone acetate and Prednisone for Prostate Cancer. Completed, enrolled 41 participants across 205 sites.

Detailed Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2011
Enrollment StartAug 9, 2011
Primary CompletionNov 29, 2016
Study CompletionApr 11, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 15.3 years ago

Interventions

abiraterone acetatedrug

1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily

Prednisonedrug

5 mg, oral, 5 mg twice daily